TD Asset Management Inc Sells 361,082 Shares of Halozyme Therapeutics, Inc. $HALO

TD Asset Management Inc trimmed its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 24.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,090,760 shares of the biopharmaceutical company's stock after selling 361,082 shares during the quarter. TD Asset Management Inc owned about 0.89% of Halozyme Therapeutics worth $56,741,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Moran Wealth Management LLC bought a new position in Halozyme Therapeutics during the second quarter worth $509,000. Envestnet Portfolio Solutions Inc. boosted its position in Halozyme Therapeutics by 46.2% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 16,506 shares of the biopharmaceutical company's stock worth $859,000 after purchasing an additional 5,214 shares during the period. Vanguard Personalized Indexing Management LLC boosted its position in Halozyme Therapeutics by 29.3% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 29,629 shares of the biopharmaceutical company's stock worth $1,541,000 after purchasing an additional 6,717 shares during the period. IFP Advisors Inc boosted its position in shares of Halozyme Therapeutics by 110.2% in the second quarter. IFP Advisors Inc now owns 4,421 shares of the biopharmaceutical company's stock valued at $233,000 after acquiring an additional 2,318 shares during the period. Finally, Maryland State Retirement & Pension System bought a new stake in shares of Halozyme Therapeutics in the second quarter valued at about $310,000. 97.79% of the stock is owned by institutional investors.

Halozyme Therapeutics Stock Down 0.4%

HALO stock opened at $66.36 on Thursday. The company has a market cap of $7.76 billion, a PE ratio of 15.19, a price-to-earnings-growth ratio of 0.36 and a beta of 1.16. The business has a 50-day simple moving average of $71.38 and a 200 day simple moving average of $62.04. Halozyme Therapeutics, Inc. has a 52 week low of $42.01 and a 52 week high of $79.50. The company has a quick ratio of 7.01, a current ratio of 8.36 and a debt-to-equity ratio of 4.54.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $1.54 EPS for the quarter, beating analysts' consensus estimates of $1.23 by $0.31. The business had revenue of $325.72 million during the quarter, compared to the consensus estimate of $282.66 million. Halozyme Therapeutics had a return on equity of 150.85% and a net margin of 47.28%.Halozyme Therapeutics's revenue for the quarter was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.91 earnings per share. Halozyme Therapeutics has set its FY 2025 guidance at 6.000-6.400 EPS. Sell-side analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Benchmark boosted their target price on shares of Halozyme Therapeutics from $75.00 to $90.00 and gave the company a "buy" rating in a research report on Wednesday, September 24th. Morgan Stanley boosted their target price on shares of Halozyme Therapeutics from $75.00 to $80.00 and gave the company an "overweight" rating in a research report on Monday, August 18th. HC Wainwright reissued a "buy" rating and issued a $90.00 target price on shares of Halozyme Therapeutics in a research report on Wednesday. Zacks Research cut shares of Halozyme Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 6th. Finally, JMP Securities boosted their target price on shares of Halozyme Therapeutics from $78.00 to $91.00 and gave the company a "market outperform" rating in a research report on Wednesday, August 6th. Six research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and an average target price of $73.00.

Insiders Place Their Bets

In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 20,000 shares of the business's stock in a transaction dated Wednesday, September 10th. The stock was sold at an average price of $75.71, for a total transaction of $1,514,200.00. Following the completion of the transaction, the chief financial officer owned 24,306 shares of the company's stock, valued at approximately $1,840,207.26. The trade was a 45.14% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Helen Torley sold 20,000 shares of the business's stock in a transaction dated Wednesday, October 1st. The stock was sold at an average price of $75.35, for a total value of $1,507,000.00. Following the transaction, the chief executive officer directly owned 733,719 shares of the company's stock, valued at approximately $55,285,726.65. The trade was a 2.65% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 108,227 shares of company stock valued at $7,779,595. 2.40% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

Want to see what other hedge funds are holding HALO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.